Rheumatology

ARTICLE: Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis AUTHORS: David Fiorentino, Christopher… Read More »Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis

ARTICLE: Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course AUTHORS: Ji Soo Kim, Adrianne Woods, Laura Gutierrez-Alamillo, Maureen Laffoon, Fredrick… Read More »Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course

ARTICLE: Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis AUTHORS: Iago Pinal-Fernandez, Angela Quintana, Jose Cesar Milisenda, Maria Casal-Dominguez, Sandra Muñoz-Braceras, Assia Derfoul, Jiram Torres-Ruiz, Katherine Pak, Stefania Dell'Orso, Faiza Naz, Gustavo… Read More »Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis

ARTICLE: Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis AUTHORS: Anne R Bass, Noha Abdel-Wahab, Pankti… Read More »Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis

ARTICLE: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) AUTHORS: Michelle Petri, Ian N Bruce, Thomas Dörner, Yoshiya Tanaka, Eric… Read More »Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)